I had a couple of posts "over there" I thought might be worth reposting over here.
Here is a thought that should literally send shivers down the spine of anyone holding a short position in Cellceutix. The float (available shares) is 77.81 million shares. 77.81 X $1.75 = ~140 million dollars.
So for less than half of what United Therapeutics received for their last Rare Pediatric Disease Priority Review Voucher they could buy up the entire float of Cellceutix. They have a pretty good idea of what that voucher is worth, I bet they might like to have another one to sell in the future. As a free bonus they could be a major share holder in a Company with, the first new class of antibiotic in the last 20 years that is about to begin a world wide Phase 3 trial, a possible treatment for Psoriasis that is wrapping up a phase 2 and is a pill not an injection and is way cheaper than biologics, then there is that Cancer/ oral mucositis drug that could be a blockbuster drug. I'll ignore the pre-clinical compounds (Autism drug etc.)
So if one entity controlled the entire float they could do something like this:
"The recent increase was after KaloBios CEO, Martin Shkreli, tweeted on November 26: “I spoke with my counsel & advisers and decided to stop lending my $KBIO shares out until I better understand the advantages of doing so.”
"Talk about a nightmare trade.
Joe Campbell had $37,000 in his online brokerage account when he went to bed on Wednesday night. By the time he woke up, not only had all that money vanished, but the amateur trader actually owed ETrade more than $100,000.
No, Campbell wasn't the victim of evil hackers. He was the victim of poor judgment -- and his ordeal should serve as a lesson for all investors.
Campbell was in such a desperate spot that he even set up a GoFundMe campaign begging for help. The effort eventually raised more than $5,000, though Campbell also took flak.
According to his GoFundMe page, Campbell placed a risky bet on Wednesday against KaloBio, (KBIO) a little known pharmaceutical company that was trading at $2. Campbell was basically betting that the stock would fall further.
Big bet backfires
When a friend who knew about his bet called the next morning to ask if he was okay, Campbell said his "heart dropped." He feared all $37,000 in his account might have been lost.
Reality was far worse. KaloBios shares had surged to $16 after the controversial former hedge fund manager Martin Shkreli had bought a stake. ETrade (ETFC) said not only had the account gone to zero, but he was on the hook for $106,445.56.
"Never in my wildest dreams did I imagine Etrade would NOT have some sort of stop or circuit breaker in place," Campbell wrote, adding that he was upset the online brokerage didn't notify him.
So-called "short" bets are always risky because in theory there is no limit to potential losses if the stock goes the other way. This trade was even more dangerous because Campbell held the position overnight, when he couldn't have done anything if the stock moved up. Plus, KaloBios is a tiny stock, making it susceptible to violent moves, in both directions. "
http://money.cnn.com/2015/11/20/investing/tra...s-shkreli/
Put that under your pillow and sleep tight those of you holding the nearly 1 million (legal shorts). No thanks!
Here is a thought that should literally send shivers down the spine of anyone holding a short position in Cellceutix. The float (available shares) is 77.81 million shares. 77.81 X $1.75 = ~140 million dollars.
So for less than half of what United Therapeutics received for their last Rare Pediatric Disease Priority Review Voucher they could buy up the entire float of Cellceutix. They have a pretty good idea of what that voucher is worth, I bet they might like to have another one to sell in the future. As a free bonus they could be a major share holder in a Company with, the first new class of antibiotic in the last 20 years that is about to begin a world wide Phase 3 trial, a possible treatment for Psoriasis that is wrapping up a phase 2 and is a pill not an injection and is way cheaper than biologics, then there is that Cancer/ oral mucositis drug that could be a blockbuster drug. I'll ignore the pre-clinical compounds (Autism drug etc.)
So if one entity controlled the entire float they could do something like this:
"The recent increase was after KaloBios CEO, Martin Shkreli, tweeted on November 26: “I spoke with my counsel & advisers and decided to stop lending my $KBIO shares out until I better understand the advantages of doing so.”
"Talk about a nightmare trade.
Joe Campbell had $37,000 in his online brokerage account when he went to bed on Wednesday night. By the time he woke up, not only had all that money vanished, but the amateur trader actually owed ETrade more than $100,000.
No, Campbell wasn't the victim of evil hackers. He was the victim of poor judgment -- and his ordeal should serve as a lesson for all investors.
Campbell was in such a desperate spot that he even set up a GoFundMe campaign begging for help. The effort eventually raised more than $5,000, though Campbell also took flak.
According to his GoFundMe page, Campbell placed a risky bet on Wednesday against KaloBio, (KBIO) a little known pharmaceutical company that was trading at $2. Campbell was basically betting that the stock would fall further.
Big bet backfires
When a friend who knew about his bet called the next morning to ask if he was okay, Campbell said his "heart dropped." He feared all $37,000 in his account might have been lost.
Reality was far worse. KaloBios shares had surged to $16 after the controversial former hedge fund manager Martin Shkreli had bought a stake. ETrade (ETFC) said not only had the account gone to zero, but he was on the hook for $106,445.56.
"Never in my wildest dreams did I imagine Etrade would NOT have some sort of stop or circuit breaker in place," Campbell wrote, adding that he was upset the online brokerage didn't notify him.
So-called "short" bets are always risky because in theory there is no limit to potential losses if the stock goes the other way. This trade was even more dangerous because Campbell held the position overnight, when he couldn't have done anything if the stock moved up. Plus, KaloBios is a tiny stock, making it susceptible to violent moves, in both directions. "
http://money.cnn.com/2015/11/20/investing/tra...s-shkreli/
Put that under your pillow and sleep tight those of you holding the nearly 1 million (legal shorts). No thanks!
